XNASLSB
Market cap107mUSD
Dec 23, Last price
3.07USD
1D
3.72%
1Q
300.00%
Name
YS Biopharma Co Ltd
Chart & Performance
P/E
—
P/S
0.16
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
687m
+36.63%
Net income
-145m
L+37.24%
CFO
-182m
L+5.14%
Profile
Summit Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Central, Hong Kong.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2023‑03 | 2022‑03 | 2021‑03 | |
| Income | |||
Revenues | 687,201 36.63% | 502,950 95.69% | |
Cost of revenue | 805,382 | 601,054 | |
Unusual Expense (Income) | |||
NOPBT | (118,181) | (98,104) | |
NOPBT Margin | |||
Operating Taxes | 1,134 | 4,937 | |
Tax Rate | |||
NOPAT | (119,315) | (103,041) | |
Net income | (145,479) 37.24% | (106,004) -44.74% | |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | 198,490 | 116,056 | |
Long-term debt | 311,242 | 279,461 | |
Deferred revenue | 23,607 | 30,054 | |
Other long-term liabilities | 8,792 | 1,370,221 | |
Net debt | 139,624 | 124,449 | |
| Cash flow | |||
Cash from operating activities | (182,469) | (173,545) | |
CAPEX | (57,050) | (298,932) | |
Cash from investing activities | (56,982) | (298,924) | |
Cash from financing activities | 317,450 | 364,558 | |
FCF | (219,988) | (537,784) | |
| Balance | |||
Cash | 370,108 | 271,068 | |
Long term investments | |||
Excess cash | 335,748 | 245,920 | |
Stockholders' equity | (1,928,438) | (137,250) | |
Invested Capital | 3,187,920 | 1,217,973 | |
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | 93,058 | 92,175 | |
Price | |||
Market cap | |||
EV | |||
EBITDA | (81,493) | (66,950) | |
EV/EBITDA | |||
Interest | 30,858 | 2,717 | |
Interest/NOPBT | |||